Lateral lumbar interbody fusion is a minimally invasive procedure to remove spinal discs damaged by degenerative disc disease, and replace them with bone graft implants. By entering through the patient’s side, the major back muscles and nerves are spared. Vertebral Technologies, Inc. (VTI) has received 510(k) clearance from the FDA for the InterFuse Lateral (Interfuse L), which uses a proprietary rail and slot technology to deliver the graft implants. The implants themselves are modularized, allowing physicians to replace larger discs with the implant through smaller incisions, further reducing muscle and nerve damage done. Rather than a one-size-fit-all implant, the modular approach also allows physicians to provide a more customized solution for the patients’ anatomy. The InterFuse L implants are then assembled in the disc space itself.
VTI will introduce four different Interfuse L designs for each of the major approaches, each of which were cleared by the FDA, and are expected to have an alpha launch in mid-November. The InferFuse L will be part of VTI’s portfolio of products that already include InterFuse T and InterFuse S, with the InterFuse T-Duo in the pipeline.